# A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

> **NCT07243171** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hangzhou Sciwind Biosciences Co., Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Overweight and/or Obesity
- Weight Management

## Interventions

- **DRUG:** ecnoglutide tablets
- **DRUG:** placebo with matching dosage

## Key facts

- **NCT ID:** NCT07243171
- **Lead sponsor:** Hangzhou Sciwind Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-18
- **Primary completion:** 2026-08-03
- **Final completion:** 2026-11-22
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07243171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07243171, "A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07243171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*